An ever-increasing demand for novel antimicrobials to treat life-threatening infections
caused by the global spread of multidrug-resistant bacterial pathogens stands in stark …

Antibacterial resistance is one of the greatest threats to human health. The development of
new therapeutics against bacterial pathogens has slowed drastically since the approvals of …

Microorganisms produce small bioactive compounds as part of their secondary or
specialised metabolism. Often, such metabolites have antimicrobial, anticancer, antifungal …

Many microorganisms produce natural products that form the basis of antimicrobials,
antivirals, and other drugs. Genome mining is routinely used to complement screening …

Genetically encoded small molecules (secondary metabolites) play eminent roles in
ecological interactions, as pathogenicity factors and as drug leads. Yet, these chemical …

All organisms produce specialized organic molecules, ranging from small volatile chemicals
to large gene-encoded peptides, that have evolved to provide them with diverse cellular and …

The use of life-saving antibiotics has long been plagued by the ability of pathogenic bacteria
to acquire and develop an array of antibiotic resistance mechanisms. The sum of these …

Bacteria provide a rich source of natural products with potential therapeutic applications,
such as novel antibiotic classes or anticancer drugs. Bioactivity-guided screening of …

Developments in computational omics technologies have provided new means to access
the hidden diversity of natural products, unearthing new potential for drug discovery. In …

Covering: 2016 to 2021 With genetic information available for hundreds of thousands of
organisms in publicly accessible databases, scientists have an unprecedented opportunity …